Onychomycosis Treatment Market By Product Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Onychomycosis Treatment Market
Onychomycosis Treatment Market: By Product Type (Tablet, Nail Paint, Device –Laser Beam and Ultra Sound) & By Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)
Report Code : HCR 0328
Updated Date: 15 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Onychomycosis Treatment – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Onychomycosis Treatment – Market Forces
   4.1. Drivers
      4.1.1. Increased prevalence rate of diabetic patients and geriatric population.
      4.1.2. Consistent rise in the prevalence of onychomycosis infections
      4.1.3. Development of novel medications
   4.2. Restrains
      4.2.1. Increased circulation of off label products
      4.2.2. Negligence towards this infection especially in less developed economies
   4.3. Opportunities
      4.3.1 Emerging Economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Onychomycosis Treatment – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Onychomycosis Treatment Market, By Product Type
   6.1. Tablet
   6.2. Nail Paint
   6.3. Device –Laser Beam and Ultra Sound Migraines
   6.4. Others
7. Onychomycosis Treatment Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Onychomycosis Treatment – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. GlaxoSmithKline Pharmaceuticals Limited
   9.2. Pfizer Inc.
   9.3. Abbott Laboratories
   9.4. Galaderma
   9.5. Janssen Global Services, LLC
   9.6. NuvoLase, Inc
   9.7. Cutera
   9.8. Sciton Inc,
   9.9. Novartis AG
   9.10. Bristol Meyer Squibb
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of expert Insights
   10.6. Disclaimer
Onychomycosis is a nail infection caused by fungus–Trichophyton rubrum. Currently, around 2-3% of the U.S. population are suffering from onynchomycosis. Onychomycosis is majorly four types which include distal subungual onychomycosis, proximal subungual onychomycosis, and white superficial onychomycosis and candida infections of the nail. Globally, increased prevalence rate of diabetic patients and geriatric population, consistent raise in the prevalence of onychomycosis infections, rise in awareness among common people regarding diagnosis and treatment of  Onychomycosis, and development of novel medications are the prime growth drivers of Onychomycosis market. In addition, emerging economies such as China, India and others, will create new opportunities for global Onychomycosis market. However, Increased circulation of off label products and  Negligence towards this infection especially in less developed economies are the key restraints for global Onychomycosis treatment market.    

Onychomycosis Treatment Market

Geographically, Asia-Pacific is considered as an emerging market due to growing market penetration in this region. Increasing disposable income among population is also accounted for the Onychomycosis Treatment market growth in Asia-Pacific countries. Rest of the world (RoW) holds fourth position in the global Onychomycosis Treatment market due to poor economic and health condition in most of the African countries. RoW market growth will be fuelled by extensive increase in healthcare infrastructure in Brazil and Mexico.

This report identifies the onychomycosis treatment market size in for the year 2016-2021, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to onychomycosis treatment market.

This report is segmented into product type. Some of the major product type covered in this report are as follows:
  • Global Onychomycosis Treatment Market By Product Type: Tablet, Nail Paint, Device –Laser Beam and Ultra Sound, and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Onychomycosis Treatment in each of the region.

This report identifies all the major companies operating in the global Onychomycosis Treatment market. Some of the major companies’ profiles in detail are as follows:

  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Inc.
  • Abbott Laboratories
  • Galaderma
  • Janssen Global Services, LLC
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports